Diane Parks - Soligenix Director
| SNGX Stock | USD 0.40 0.01 2.44% |
Director
Ms. Diane L. Parks is Director of the Company. Ms. Parks is an accomplished businesswoman and commercial executive with an extensive record of driving profitable growth for large pharmaceutical and biotech companies. With a successful career spanning more than 30 years, she served most recently as Senior Vice President and Head of US Commercial for Kite Pharma, Inc., where she was responsible for the launch of Yescarta, the first CAR T therapy for large Bcell lymphoma. Prior to that, she served as Vice President and Head of Global Marketing for Pharmacyclics, Inc., where she was responsible for the marketing strategy and launch of Imbruvica in Waldenstrom macroglobulinemia, chronic lymphocytic leukemia and mantle cell lymphoma. Ms. Parks also previously served as Vice President of Sales for Amgen Inc. where she was responsible for the hospital sales team and subsequently for the Nephrology team supporting Epogen and Sensipar, and as Senior Vice President, Specialty Biotherapeutics for Genentech, Inc., where she led the launches and sales forces for such products as Nutropin AQ Pen, Xolair and Raptiva . She is currently on the Boards of Calliditas Therapeutics AB and Healogix LLC since 2019.
| Tenure | 5 years |
| Address | 29 Emmons Drive, Princeton, NJ, United States, 08540 |
| Phone | 609 538 8200 |
| Web | https://www.soligenix.com |
Diane Parks Latest Insider Activity
Tracking and analyzing the buying and selling activities of Diane Parks against Soligenix stock is an integral part of due diligence when investing in Soligenix. Diane Parks insider activity provides valuable insight into whether Soligenix is net buyers or sellers over its current business cycle. Note, Soligenix insiders must abide by specific rules, including filing SEC forms every time they buy or sell Soligenix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Diane Parks over two weeks ago Acquisition by Diane Parks of 30928 shares of Soligenix at 0.97 subject to Rule 16b-3 |
Soligenix Management Efficiency
The company has return on total asset (ROA) of (0.3997) % which means that it has lost $0.3997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (237.8376) %, meaning that it created substantial loss on money invested by shareholders. Soligenix's management efficiency ratios could be used to measure how well Soligenix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.66 in 2024. Return On Capital Employed is likely to rise to -2.22 in 2024. At this time, Soligenix's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 909.3 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 275.5 K in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Brian Schreiber | Windtree Therapeutics | N/A | |
| Geert Cauwenbergh | Phio Pharmaceuticals Corp | 64 | |
| Joseph Mahady | Windtree Therapeutics | 61 | |
| Harald Borje | Windtree Therapeutics | 52 | |
| Daniel Geffken | Windtree Therapeutics | 60 | |
| Curtis Lockshin | Phio Pharmaceuticals Corp | 55 | |
| Jan Lundblad | Windtree Therapeutics | 54 | |
| Jorgen Nordlund | Windtree Therapeutics | 51 | |
| Keith Brownlie | Phio Pharmaceuticals Corp | 65 | |
| Paul Dorman | Phio Pharmaceuticals Corp | 78 | |
| Jorgen Per | Windtree Therapeutics | 51 | |
| Mahady Joseph | Windtree Therapeutics | 62 | |
| Paivo Eerola | Windtree Therapeutics | N/A | |
| Someit MD | Zura Bio Limited | 34 | |
| Bruce Peacock | Windtree Therapeutics | 66 | |
| Marvin Rosenthale | Windtree Therapeutics | 80 | |
| Lindsay Rosenwald | Avenue Therapeutics | 69 | |
| Tomas Rudenstam | Windtree Therapeutics | 55 | |
| Malte Roggentin | Windtree Therapeutics | 61 | |
| Jonathan Freeman | Phio Pharmaceuticals Corp | N/A | |
Management Performance
| Return On Equity | -237.84 | ||||
| Return On Asset | -0.4 |
Soligenix Leadership Team
Elected by the shareholders, the Soligenix's board of directors comprises two types of representatives: Soligenix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Soligenix. The board's role is to monitor Soligenix's management team and ensure that shareholders' interests are well served. Soligenix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Soligenix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jerome Zeldis, Independent Director | ||
| Richard Straube, Senior Vice President and Chief Medical Officer | ||
| Marco Brughera, Director | ||
| Gregg Lapointe, Independent Director | ||
| Keith Brownlie, Independent Director | ||
| Karen Krumeich, CFO, Senior Vice President | ||
| Richard Dunning, Ex Officer | ||
| Anthony Lapointe, Independent Director | ||
| Diane Parks, Director | ||
| Oreola Donini, Chief Scientific Officer and Sr. VP | ||
| Christopher Schaber, Chairman, CEO and Pres | ||
| Joseph Warusz, Acting CFO, Vice President - Finance, Corporate Secretary | ||
| Mark Pearson, Director | ||
| Robert Rubin, Independent Director | ||
| CGMA CPA, CFO VP | ||
| MSc MD, Senior Officer |
Soligenix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Soligenix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -237.84 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (8.73) % | ||||
| Current Valuation | (680.78 K) | ||||
| Shares Outstanding | 14.24 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 2.70 % | ||||
| Number Of Shares Shorted | 115.8 K | ||||
| Price To Earning | (1.67) X | ||||
| Price To Book | 1.61 X |
Currently Active Assets on Macroaxis
When determining whether Soligenix offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soligenix's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soligenix Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soligenix Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soligenix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Soligenix Stock please use our How to Invest in Soligenix guide.Note that the Soligenix information on this page should be used as a complementary analysis to other Soligenix's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Soligenix Stock analysis
When running Soligenix's price analysis, check to measure Soligenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Soligenix is operating at the current time. Most of Soligenix's value examination focuses on studying past and present price action to predict the probability of Soligenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Soligenix's price. Additionally, you may evaluate how the addition of Soligenix to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Soligenix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soligenix. If investors know Soligenix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soligenix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Revenue Per Share 0.108 | Quarterly Revenue Growth (0.33) | Return On Assets (0.40) | Return On Equity (237.84) |
The market value of Soligenix is measured differently than its book value, which is the value of Soligenix that is recorded on the company's balance sheet. Investors also form their own opinion of Soligenix's value that differs from its market value or its book value, called intrinsic value, which is Soligenix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soligenix's market value can be influenced by many factors that don't directly affect Soligenix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soligenix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Soligenix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soligenix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.